Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome
Monique C. Minnema,
Eva Kimby,
Shirley D’Sa,
Luc-Matthieu Fornecker,
Stéphanie Poulain,
Tom J. Snijders,
Efstathios Kastritis,
Stéphane Kremer,
Aikaterini Fitsiori,
Laurence Simon,
Frédéric Davi,
Michael Lunn,
Jorge J. Castillo,
Christopher J. Patterson,
Magali Le Garff-Tavernier,
Myrto Costopoulos,
Véronique Leblond,
Marie-José Kersten,
Meletios A. Dimopoulos,
Steven P. Treon
Affiliations
Monique C. Minnema
Department of Hematology, UMC Utrecht Cancer Center, the Netherlands
Eva Kimby
Hematology Center, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Shirley D’Sa
Cancer Division, University College London Hospitals NHS Foundation Trust, UK
Luc-Matthieu Fornecker
Department of Oncology and Hematology, Hôpital Universitaires de Strasbourg and Université de Strasbourg, France
Stéphanie Poulain
Service d’Hématologie-Immunologie-Cytogénétique, Centre Hospitalier de Valenciennes/Laboratoire d’Hématologie, Centre de Biologie et Pathologie, CHRU de Lille/INSERM, France
Tom J. Snijders
Department of Neurology & Neurosurgery, Brain Center Rudolf Magnus, UMC Utrecht, The Netherlands
Efstathios Kastritis
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
Stéphane Kremer
Pôle d’Imagerie–Neuroradiologie, Hôpital de Hautepierre/CHU Strasbourg, France
Aikaterini Fitsiori
Pôle d’Imagerie–Neuroradiologie, Hôpital de Hautepierre/CHU Strasbourg, France
Laurence Simon
Department of Oncology and Hematology, Hôpital Universitaires de Strasbourg and Université de Strasbourg, France
Frédéric Davi
Laboratory of Hematology, Hôpital Pitié Salpêtrière, Paris, France
Michael Lunn
Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
Jorge J. Castillo
Bing Center for Waldenstrom’s Macroglobulinemia, Dana Farber Cancer Institute and Harvard Medical; School, Boston, MA, USA
Christopher J. Patterson
Bing Center for Waldenstrom’s Macroglobulinemia, Dana Farber Cancer Institute and Harvard Medical; School, Boston, MA, USA
Magali Le Garff-Tavernier
Laboratory of Hematology, Hôpital Pitié Salpêtrière, Paris, France
Myrto Costopoulos
Laboratory of Hematology, Hôpital Pitié Salpêtrière, Paris, France
Véronique Leblond
AP-HP Hôpital Pitié Salpêtrière, UPMC univ Paris, France
Marie-José Kersten
Department of Hematology, Academic Medical Center, Amsterdam, the Netherlands
Meletios A. Dimopoulos
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
Steven P. Treon
Bing Center for Waldenstrom’s Macroglobulinemia, Dana Farber Cancer Institute and Harvard Medical; School, Boston, MA, USA
Bing Neel syndrome is a rare disease manifestation of Waldenström’s macroglobulinemia that results from infiltration of the central nervous system by malignant lymphoplasmacytic cells. In this guideline we describe the clinical symptoms, as well as the appropriate laboratory and radiological studies, that can aid in the diagnosis. The presentation of Bing Neel syndrome may be very diverse, and includes headaches, cognitive deficits, paresis, and psychiatric symptoms. The syndrome can present in patients with known Waldenström’s macroglobulinemia, even in the absence of systemic progression, but also in previously undiagnosed patients. Diagnostic work-up should include cerebral spinal fluid analysis with multiparameter flow cytometry to establish B-cell clonality, protein electrophoresis and immunofixation for the detection and classification of a monoclonal protein as well as molecular diagnostic testing for immunoglobulin gene rearrangement and mutated MYD88. MRI of the brain and spinal cord is also essential. The second challenge is to expand our knowledge of prognosis and treatment outcome. Prospective clinical trials on Bing Neel syndrome patients that employ uniform treatment along with appropriate laboratory cerebral spinal fluid assessments and standardized MRI protocols will be invaluable, constituting a significant step forward in delineating treatment outcome for this intriguing disease manifestation.